Foresee Pharmaceuticals (TPEx: 6576) announced completion of its Casppian Phase 3 clinical trial for FP-001 42 mg, an investigational treatment ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE